Latest News

Orzeyful is the first orexin-restoring therapy for NT1, backed by the phase 3 FirstLight and RadiantLight trials.

Schwartz must immediately address a measles crisis that has reached a 35-year high in the US, as well as a growing Cyclospora outbreak

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

The findings point to persistent vaccine hesitancy and access gaps in the years since the COVID-19 pandemic, with authors calling for stronger clinician recommendations and school-based vaccination sites.

In a phase 4 study, 90.9% of patients receiving preoperative suzetrigine-based multimodal therapy avoided opioid rescue after aesthetic or reconstructive surgery.

The future of 340B depends on integrating quality, compliance, technology, and pharmacist-led care to improve patient outcomes and strengthen audit readiness.

FDA-approved colorectal cancer blood tests—Shield, Epi proColon, SimpleScreen—expand blood-based screening, but positives still need colonoscopy.

Revumenib and ziftomenib in NPM1-mutated AML: practical guidance on differentiation syndrome, QTc monitoring, and drug interactions.

Zongertinib offers durable activity in HER2-mutant NSCLC while highlighting pharmacists’ essential role in biomarker verification, dosing, medication review, adherence, and toxicity management.

A randomized trial found that medically tailored groceries cut hemoglobin A1C by 0.40 points and sharply improved food security in adults with type 2 diabetes.

Pafolacianine enables fluorescence-guided lung cancer surgery, with inpatient pharmacy integral to safe procurement, preparation, and interdisciplinary coordination.

From isotope decay to patient access, radiopharmaceuticals present unique challenges for oncology pharmacists.

A new machine learning version of the Martin-Hopkins equation matches the original's accuracy while making implementation easier for laboratories.

FDA-cleared HPV self-collection kits like Teal Wand expand cervical cancer screening; pharmacists support follow-up, HPV education, and Gardasil.

Suzetrigine prescriptions approached 1 million in the first half of 2026 as reimbursed access expanded, signaling growing adoption of nonopioid acute pain treatment.

Oral liposomal vitamin C dietary supplementation demonstrates improved pharmacokinetics and pharmacodynamics, but a difference on immunity is inconclusive.

A cone snail venom–derived peptide selectively inhibited the norepinephrine transporter and reduced inflammatory pain behavior without sedation in mice.

Darren Evans, PharmD, discusses what pharmacy leaders at other rural or regional health systems should consider before building a similar model.

Radiopharmaceuticals force oncology pharmacists to master safety, timing, waste, and costs—see how departments build radioactive therapy workflows.

The FDA approved once-daily centanafadine (Simtriyo), the first norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD in adults and children aged 6 years and older weighing at least 20 kg.

The FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan introduces PSMA-targeted radioligand therapy to mHSPC.